Carrington Laboratories, Inc. Subsidiary DelSite Biotechnologies, Inc. Signs Technology License Agreement With ElSohly Laboratories

IRVING, Texas, Feb. 19 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. today announced its wholly-owned subsidiary DelSite Biotechnologies, Inc. has signed a technology license agreement with privately held ElSohly Laboratories, Inc., of Oxford, Mississippi, covering the use of GelSite(R) Polymer technology in formulating an anticancer drug. Terms of the agreement were not disclosed.

Both DelSite Biotechnologies and ElSohly Laboratories have Cooperative Research and Development Agreements (CRADAs) with the National Cancer Institute (NCI). Whereas DelSite's CRADA covers the development of a nasal powder vaccine for Human Papillomavirus (HPV), ElSohly's CRADA covers an anticancer drug that has demonstrated anticancer activity and reduction of metastasis of cancer cells in more than one type of cancer.

"Our interest in DelSite's technology is to take advantage of its GelSite(R) polymer's unique chemical and stabilizing characteristics in formulating our new anticancer drug candidate. We anticipate that the GelSite(R) polymer will enhance the solubility and extend the release time of our lead drug candidate and analogs currently under development in collaboration with the National Center for Natural Products Research at the University of Mississippi," stated Dr. Mahmoud ElSohly, president and laboratory director of ElSohly Laboratories.

Dr. Yawi Ni, senior scientist at DelSite, said "This agreement allows for the GelSite(R) polymer to be used to stabilize and deliver a molecule smaller than we have worked with in the past. We look forward to being involved with this promising molecule and its analogs in the anticancer area. Naturally, it is exciting that our technology is now involved in two key areas of NCI research."

About ElSohly Laboratories

ElSohly Laboratories is a privately held company specializing in naturally derived therapeutics. One of its drug candidates has undergone human clinical trial in Europe. Funding for product development comes from private and government contracts as well as sale of reference standards for organization involved in the National Laboratory Certification Program. The Company has been in business for over 20 years.

About DelSite

Carrington's wholly-owned subsidiary DelSite Biotechnologies, Inc. is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. DelSite is currently developing a nasal powder vaccine using its GelVac. formula with the H5N1 avian flu antigen. DelSite is also in agreement with other companies working to develop vaccines for HIV and Bacillary Dysentary using GelVac(TM) technology. This work on influenza vaccine is partially funded by two grants from the Department of Health and Human Services. For more information, visit .

About Carrington

Carrington Laboratories, Inc., is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington raw materials from Aloe vera L. are the only raw materials from the plant with the DSHEA claim of enhancing the immune system.

All Carrington facilities are operated under organic systems with the farming operation in Costa Rica being organic certified by a government agency and raw materials produced in Costa Rica are kosher certified. Carrington products are marketed in the US, Latin America, EU and the Far East.

Carrington and DelSite technologies are protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit .

Certain statements in this release concerning Carrington may be forward- looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission, including the Form 10-Q, filed November 14, 2006.

Carrington Laboratories, Inc.

CONTACT: Carlton E. Turner, Chief Executive Officer of CarringtonLaboratories, Inc., +1-972-518-1300

Back to news